Makhni Svetlana Ni 4
4 · Prime Medicine, Inc. · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
Prime Medicine (PRME) CFO Svetlana Makhni Receives 800,000-Share Award
What Happened
Makhni Svetlana Ni (Chief Financial Officer) received a derivative equity award on April 16, 2026 for 800,000 shares (reported as a grant, transaction code A). The award was recorded at $0.00 cash consideration — this is a grant of a vested/vesting right (an option or similar derivative), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-04-16; Filing date: 2026-04-17 (timely filing).
- Transaction type/code: A (award/grant of a derivative security). Price reported: $0.00; aggregate cash paid: $0.
- Vesting: 25% of shares underlying the option vest on April 16, 2027; the balance vests monthly in equal installments over the following 36 months, subject to continued service (footnote F1).
- Shares owned after transaction: not specified in the provided summary — see the Form 4 for the reporter’s total holdings.
- No sale or exercise occurred in this filing; this is a compensation grant.
Context
This filing reports a standard executive equity grant (derivative award) meant for retention/compensation. Such awards do not involve immediate market purchases or sales and should be interpreted differently than open-market buys or disposals; they indicate compensation alignment rather than a direct bullish or bearish trading signal.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-04-16+800,000→ 800,000 totalExercise: $3.67Exp: 2036-04-16→ Common Stock (800,000 underlying)
Footnotes (1)
- [F1]25% of the shares underlying this option shall vest on April 16, 2027 and the balance will vest monthly in equal instalments over the following 36 months, subject to the Reporting Person's continued service on each such vesting date.